Article Listing - Study results suggest B-MS/Ostuka's Abilify is safe for long-term schizophrenia combination therapy

EUROPEAN ASTHMA TREATMENT MARKET

6 April 1992

Sales of beta-2 agonists in Europe will grow from $485 million in 1990 to almost $983 million by 1995, or...

LOWER SALES/PROFIT FOR BAYER ITALY

6 April 1992

In line with the group's overall international performance, Bayer Italia reports lower sales and profits in 1991. The subsidiary of...

US PHARMACY COMPOUNDING GUIDE

6 April 1992

The US Food and Drug Administration has, for the first time, issued a pharmacist compounding compliance guide, due to the...

Italian raw materials sales

6 April 1992

The Italian pharmaceutical raw materials market expanded by 8% in 1991 to 2,500 billion lire ($2.1 billion), according to the...

BTG SALE COMPLETED

6 April 1992

The sale of British Technology Group by the UK government to a management and employee buy-out consortium was completed at...

DURAMED'S ISONIAZID

6 April 1992

The resurgence of tuberculosis brought about by the AIDS epidemic has caused generic drugs company Duramed Pharmaceut-icals to resume manufacture...

MILES STAFF CUTS

6 April 1992

Miles Inc of the USA is to reduce its workforce at its Diagnostics Business Group by 600, around 9%. The...

ARES-SERONO GAINS RIGHTS TO CUROSURF

6 April 1992

Swiss pharmaceutical group Ares-Serono has acquired exclusive marketing rights in most European territories for a natural pulmonary surfactant product, Curosurf,...

STOCK MARKET COMMENTARY: NEW YORK

6 April 1992

NEW YORK: share prices moved up and down during the reporting week, first with lower car sales pushing the Dow...

ICH STEERING COMMITTEE MEETING

6 April 1992

The Steering Committee for the Second International Conference on Harmonization (ICH) of technical requirements for the registration of pharmaceutical products...

Showing 94491-94500 of 95368 articles